Proniras

Developing novel small-molecule therapeutics for substance use and CNS disorders

placeSeattle, Washington, United States calendar_todayFounded 2018 groups2 employees language proniras.com

Innovation

2 patent families — focus: Human necessities; filing pace steady. Cited 13 times.

YearFilings
20222
20232
20242
20252

Investor mix

8 investors on record; lead investors include Accelerator Life Science Partners, Arch Venture Partners.

Investor typeCountShare
Venture capital450%
Other / undisclosed450%
Coming soon